EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Statistical and practical considerations in planning and conduct of dose-optimization trials

Ying Yuan iD, Heng Zhou, Suyu Liu

Clinical Trials · 2024-06 · 21 (3) · 273-286

DOI: 10.1177/17407745231207085 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Trials, online erschienen am 19.01.2024. Verfasst von Ying Yuan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Research Design, Maximum Tolerated Dose. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration launched Project Optimus with the aim of shifting the paradigm of dose-finding and selection toward identifying the optimal biological dose that offers the best balance between benefit and risk, rather than the maximum tolerated dose. However, achieving dose optimization is a challenging task that involves a variety of factors and is considerably more complicated than identifying the maximum tolerated dose, both in terms of design and implementation. This article provides a comprehensive review of various design strategies for dose-optimization trials, including phase 1/2 and 2/3 designs, and highlights their respective advantages and disadvantages. In addition, practical considerations for selecting an appropriate design and planning and executing the trial are discussed. The article also presents freely available software tools that can be utilized for designing and implementing dose-optimization trials. The approaches and their implementation are illustrated through real-world examples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignMaximum Tolerated DoseHumansDose-Response Relationship, DrugSoftwareClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicUnited StatesUnited States Food and Drug AdministrationClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Optimal doseProject Optimusadaptive designbenefit–risk trade-off

Autor:innen und Institutionen

  • Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Biostatistics and Research Decision Sciences, Merck and Co., Inc, Rahway, NJ, USA.

ORCID-Profile: Ying Yuan

Zitieren

APA

Yuan, Y., Zhou, H., & Liu, S. (2024). Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials, 21(3), 273-286. https://doi.org/10.1177/17407745231207085

Vancouver

Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials. 2024;21(3):273-286. doi:10.1177/17407745231207085

BibTeX
@article{Yuan2024,
  author = {Yuan, Ying and Zhou, Heng and Liu, Suyu},
  title = {Statistical and practical considerations in planning and conduct of dose-optimization trials},
  journal = {Clinical Trials},
  year = {2024},
  volume = {21},
  number = {3},
  pages = {273--286},
  doi = {10.1177/17407745231207085}
}
Kostenlos starten →